The company's breakthrough potential comes not from collecting raw DNA, but from linking it at an individual level to a rich set of "phenotype" data, including proteomics, metabolomics, and transcriptomics. This deep, multi-layered dataset from novel populations is what unlocks actionable insights for drug discovery.

The initial goal of precision psychiatry isn't complex machine learning or perfect biomarkers. It's about systematically collecting basic, meaningful data—like cognitive function—that we already know correlates with treatment outcomes. This simple act of consistent measurement provides a powerful foundation for better understanding patients.

Many mental disorders are not just chemical imbalances but are rooted in metabolic dysfunction within brain cells. This reframing connects mental and physical health, opening new treatment avenues like diet and lifestyle changes that target cellular energy processes.

The next wave of neuroscience therapeutics is shifting from managing broad symptoms (e.g., in autism) to precision therapies. By identifying genetic underpinnings of a disease, developers can create drugs that target the specific biology of patient subpopulations, aiming for disease modification rather than just symptomatic relief.

Biomarkers for neurodegenerative diseases aren't static; they fluctuate with circadian rhythms and environmental factors. This variability complicates drug activity assessment, as a single data point can be misleading. This suggests a need for more sophisticated, longitudinal tracking in clinical trials.

Psychologist John Rottenberg argues the popular "chemical imbalance" theory is a metaphor, not a measurable biological reality like high cholesterol. Unlike cholesterol, there's no test to show a patient their "number" or that treatment is changing it, making the metaphor an oversimplification.

Large-scale genetic studies suggest many distinct brain diseases (mania, depression, ADHD, Alzheimer's) are not separate conditions. Instead, they may be different expressions of a single, general genetic susceptibility to brain dysfunction, which researchers call "Factor P".

Genomic data (DNA) provides a static blueprint of potential, not a view of the actual biological activity. True understanding requires measuring the dynamic interactions of molecules and cells within tissues "downstream." Current methods capture only fragmentary slices, missing the full picture.

A Quantitative EEG (QEEG) or "brain map" analyzes brainwave patterns to identify cognitive struggles and even sleep quality. Practitioners can often describe a person's core challenges with surprising accuracy, providing objective data before any subjective report is given.